|Articles|September 1, 2005

BioPharm International

  • BioPharm International-09-01-2005
  • Volume 18
  • Issue 9

From the Editor in Chief: From Leeches to Lawsuits

Hurricane Katrina is slamming into the Gulf Coast of the US at the moment, with wind gusts of up to 140 mph. As many as 10,000 residents of New Orleans, LA have taken shelter in the city's Superdome, while others obeyed the mandatory evacuation order and fled to safer ground earlier.

Hurricane Katrina is slamming into the Gulf Coast of the US at the moment, with wind gusts of up to 140 mph. As many as 10,000 residents of New Orleans, LA have taken shelter in the city's Superdome, while others obeyed the mandatory evacuation order and fled to safer ground earlier.

Carol L. Fisher

Historically, hurricane season hasn't been the only reason for New Orleanians to abandon hearth and home. In the 1800s, anyone who could afford to rent a cottage along Lake Pontchartrian from June to October left town when old "Bronze John," AKA yellow fever, came calling. Those too poor to escape the city burned piles of hair and hooves from slaughteryards to cleanse the disease-ridden night air. The unfortunates who failed to escape the fever's clutches also fell victim to the standard treatments of the time — blood-letting (up to several pints a day, to "lower the constitution"), with sluggish brown leeches fished from dirty gutters by apothecary assistants, and the ever popluar onion placed near or under the afflicted's bed, to "purify the lymphatic and bilious systems." When patients succumbed to the disease, families and friends accepted the death as a part of life. It wasn't the doctor's fault, and it wasn't the apothecary's fault.

Somehow we've lost our way in the last 100 years when it comes to expectations and healing. We, at least in the US, are very quick to place blame when a desired outcome is not achieved. Rather than accept the existence of risk and the responsibility of personal choice; rather than appreciate the painstaking research that supports scientific discovery and acknowledge the personal sacrifice of those who have contributed to our well-being — like Jesse Lazear, the Johns Hopkins doctor who purposely exposed himself to "loaded" (infected) Aedes aegypti mosquitoes to prove they were the Yellow Fever vector — we now expect everyone associated with healthcare to be infallible. If we're disappointed with results, our attorneys are just a phone call away.

Our knowledge base has increased substantially since the 19th century. You won't find cocaine toothache drops or tincture of opium on the shelf of your local Rite Aid. Pianists no longer cripple themselves with patented finger-stretchers. Postural remediants (metal cages with straps and wooden rollers designed for young ladies' improved handwriting), cupping glasses, and bleeding bowls are museum exhibits.

Now if only our attitudes were as enlightened as our intellects.

Carol L. Fisher, Editor in Chief

BioPharm International

cfisher@advanstar.com


Related to this article

The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.